Hprt1tm1(Pck1-cre)Vhh/Y
Vhltm1Jae/Vhltm1Jae
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6
|
abnormal kidney morphology |
J:106705
|
|
abnormal kidney vasculature morphology |
J:106705
|
|
abnormal vasodilation |
J:97652
|
|
hepatic steatosis |
J:97652
|
|
increased hemoglobin content |
J:97652
|
|
increased hepatic hemangioma incidence |
J:97652
|
|
increased vascular endothelial cell number |
J:97652
|
|
kidney cyst |
J:106705
|
|
kidney inflammation |
J:106705
|
|
polycythemia |
J:97652
|
Tg(Fabp1-cre)1Jig/0
Vhltm1Jae/Vhltm1Jae
involves: 129S4/SvJae * BALB/c * FVB/N
|
abnormal digestive system physiology |
J:93476
|
|
decreased susceptibility to induced colitis |
J:93476
|
Vhltm1.1Jae/Vhl+
involves: 129S4/SvJae * BALB/c
|
abnormal blood vessel morphology |
J:67505
|
|
hepatic steatosis |
J:67505
|
|
increased hepatic hemangioma incidence |
J:67505
|
Vhltm1.1Jae/Vhltm1.1Jae
involves: 129S4/SvJae * BALB/c
|
embryonic lethality during organogenesis, complete penetrance |
J:67505
|
Vhltm1.1Lss/Vhl+
involves: A/J
|
abnormal liver morphology |
J:85513
|
Vhltm1.1Lss/Vhl+
involves: BALB/c
|
increased hepatic hemangioma incidence |
J:85513
|
Vhltm1.1Whkr/Vhltm1.1Whkr
involves: 129S4/SvJae * C57BL/6
|
abnormal intracellular organelle physiology |
J:198361
|
|
normal
liver/biliary system phenotype |
J:198361
|
Vhltm1.1Wkr/Vhl+
involves: 129S4/SvJae * C57BL/6
|
abnormal blood vessel morphology |
J:157369
|
|
increased adenocarcinoma incidence |
J:157369
|
|
increased incidence of tumors by chemical induction |
J:157369
|
|
kidney cortex cyst |
J:157369
|
|
normal
liver/biliary system phenotype |
J:157369
|
|
preneoplasia |
J:157369
|
Vhltm1.1Wkr/Vhltm1.1Wkr
involves: 129S4/SvJae * C57BL/6
|
embryonic lethality during organogenesis, incomplete penetrance |
J:157369
|
Vhltm1Bjg/Vhltm1Bjg
Not Specified
|
abnormal limb bud morphology |
J:48254
|
|
abnormal pharyngeal arch morphology |
J:48254
|
|
embryonic growth retardation |
J:48254
|
|
embryonic lethality during organogenesis, complete penetrance |
J:48254
|
Vhltm1Jae/Vhltm1Jae
involves: 129S4/SvJae
|
decreased cell proliferation |
J:160941
|
Vhltm1Jae/Vhltm1Jae
involves: 129S4/SvJae * BALB/c
|
no abnormal phenotype detected |
J:67505
|
Vhltm1Jae/Vhltm1Jae
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae
|
increased inflammatory response |
J:107682
|
Vhltm1Jae/Vhltm1Jae
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA
|
abnormal blood vessel morphology |
J:67505
|
|
abnormal liver morphology |
J:67505
|
|
abnormal vasodilation |
J:97652
|
|
decreased body weight |
J:67505
|
|
enlarged liver |
J:67505
|
|
hepatic steatosis |
J:67505,
J:97652
|
|
increased vascular endothelial cell number |
J:97652
|
|
polycythemia |
J:67505
|
|
premature death |
J:67505
|
Vhltm1Jae/Vhltm1Jae
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * DBA
|
abnormal blood vessel morphology |
J:144666
|
|
abnormal hepatocyte morphology |
J:144666
|
|
abnormal liver morphology |
J:144666
|
|
decreased body size |
J:144666
|
|
hepatic steatosis |
J:144666
|
|
increased hematocrit |
J:144666
|
|
increased hepatocyte proliferation |
J:144666
|
|
increased liver weight |
J:144666
|
|
premature death |
J:144666
|
|
reddish skin |
J:144666
|
|
reticulocytosis |
J:144666
|
Vhltm1Jae/Vhltm1Jae
Tg(Cdh16-cre)91Igr/0
involves: 129S4/SvJae * BALB/c * C57BL/6J * ICR
|
hydronephrosis |
J:137073
|
Vhltm1Jae/Vhltm1Jae
Tg(Cdh16-cre)91Igr/0
involves: 129S4/SvJae * ICR
|
abnormal epididymis morphology |
J:137442
|
Vhltm1Jae/Vhltm1Jae
Tg(KRT14-cre)1Ipc/0
involves: 129S4/SvJae * C57BL/6 * SJL
|
alopecia |
J:144666
|
|
decreased body size |
J:144666
|
|
dilated vasculature |
J:144666
|
|
epidermal hyperplasia |
J:144666
|
|
increased keratinocyte proliferation |
J:144666
|
|
increased vascular permeability |
J:144666
|
|
reddish skin |
J:144666
|
Vhltm1Jae/Vhltm1Jae
Tg(Myh6-cre)2182Mds/0
involves: 129S4/SvJae * FVB/N
|
abnormal heart left ventricle morphology |
J:179490
|
|
cardiomyopathy |
J:179490
|
|
decreased heart rate |
J:193425
|
|
decreased mitochondrial number |
J:179490
|
|
decreased ventricle muscle contractility |
J:179490
|
|
increased angiogenesis |
J:179490
|
|
increased heart weight |
J:179490
|
|
irregular heartbeat |
J:193425
|
|
postnatal lethality, complete penetrance |
J:193425
|
|
premature death |
J:179490
|
|
prolonged QRS complex duration |
J:193425
|
|
prolonged QT interval |
J:193425
|
Vhltm1Jae/Vhltm1Jae
Tg(NPHS2-cre)295Lbh/?
involves: 129S4/SvJae * C57BL/6 * SJL
|
abnormal renal glomerulus basement membrane morphology |
J:162099
|
|
albuminuria |
J:162099
|
|
cachexia |
J:162099
|
|
decreased podocyte number |
J:162099
|
|
dilated glomerular capillary |
J:162099
|
|
dilated kidney collecting duct |
J:162099
|
|
dilated renal tubule |
J:162099
|
|
edema |
J:162099
|
|
expanded mesangial matrix |
J:162099
|
|
glomerular crescent |
J:162099
|
|
increased blood urea nitrogen level |
J:162099
|
|
increased mesangial cell number |
J:162099
|
|
increased renal glomerulus basement membrane thickness |
J:162099
|
|
kidney failure |
J:162099
|
|
podocyte foot process effacement |
J:162099
|
|
premature death |
J:162099
|
|
renal cast |
J:162099
|
|
renal glomerulus fibrosis |
J:162099
|
|
renal interstitial fibrosis |
J:162099
|
|
normal
renal/urinary system phenotype |
J:162099
|
Vhltm1Jae/Vhltm1Jae
Tg(Pax6-cre,GFP)2Pgr/0
involves: 129S4/SvJae
|
abnormal retina vasculature morphology |
J:217533
|
Vhltm1Jae/Vhltm1Jae
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129S4/SvJae * CD-1
|
abnormal angiogenesis |
J:186085
|
|
abnormal blood cell morphology/development |
J:186085
|
|
abnormal foot pad morphology |
J:186085
|
|
decreased body size |
J:186085
|
|
decreased bone marrow cell number |
J:186085
|
|
decreased lymphocyte cell number |
J:186085
|
|
enlarged spleen |
J:186085
|
|
extramedullary hematopoiesis |
J:186085
|
|
increased bone trabecula number |
J:186085
|
|
increased circulating erythropoietin level |
J:186085
|
|
increased erythrocyte cell number |
J:186085
|
|
increased erythroid progenitor cell number |
J:186085
|
|
increased hematocrit |
J:186085
|
|
increased hematopoietic stem cell number |
J:186085
|
|
increased osteoblast cell number |
J:186085
|
|
increased trabecular bone mass |
J:186085
|
|
increased trabecular bone volume |
J:186085
|
|
polycythemia |
J:186085
|
Vhltm1Lss/Vhltm1.1Lss
involves: 129X1/SvJ * C57BL/6
|
increased hepatic hemangioma incidence |
J:85513
|
|
oligozoospermia |
J:85513
|
Vhltm1Lss/Vhltm1.1Lss
Tg(ACTB-cre)1Tes/0
involves: 129X1/SvJ * C3H * C57BL/6
|
abnormal angiogenesis |
J:85513
|
|
abnormal blood vessel morphology |
J:85513
|
|
abnormal liver morphology |
J:85513
|
|
decreased Sertoli cell number |
J:85513
|
|
increased hepatic hemangioma incidence |
J:85513
|
|
male infertility |
J:85513
|
|
multinucleated giant male germ cells |
J:85513
|
|
oligozoospermia |
J:85513
|
|
premature death |
J:85513
|
|
seminiferous tubule degeneration |
J:85513
|
|
small testis |
J:85513
|
Vhltm1Lss/Vhltm1.1Lss
Tg(CAG-cre/Esr1*)1Lbe/0
involves: 129S1/Sv * 129X1/SvJ
|
abnormal blood vessel morphology |
J:110518
|
|
abnormal placenta labyrinth morphology |
J:110518
|
|
abnormal placental labyrinth vasculature morphology |
J:110518
|
|
abnormal vitelline vasculature morphology |
J:110518
|
|
decreased blood urea nitrogen level |
J:155367
|
|
decreased circulating creatinine level |
J:155367
|
|
decreased embryo size |
J:110518
|
|
decreased renal tubule apoptosis |
J:155367
|
|
decreased susceptibility to kidney reperfusion injury |
J:155367
|
|
embryo tissue necrosis |
J:110518
|
|
focal hepatic necrosis |
J:110518
|
|
hemorrhage |
J:110518
|
|
lethality throughout fetal growth and development, complete penetrance |
J:110518
|
|
pallor |
J:110518
|
|
thin placenta labyrinth |
J:110518
|
Vhltm1Lss/Vhltm1Lss
Tg(Gcg-cre)1Slib/0
either: (involves: 129X1/SvJ * A/J) or (involves: 129X1/SvJ * C57BL/6)
|
normal
endocrine/exocrine gland phenotype |
J:148174
|
|
normal
mortality/aging |
J:148174
|
Vhltm1Lss/Vhltm1Lss
Tg(Ins2-cre)25Mgn/0
either: (involves: 129X1/SvJ * C57BL/6 * DBA) or (involves: 129X1/SvJ * A/J * C57BL/6 * DBA)
|
normal
endocrine/exocrine gland phenotype |
J:148174
|
|
normal
mortality/aging |
J:148174
|
Vhltm1Lss/Vhltm1Lss
Tg(Pdx1-cre)89.1Dam/0
either: (involves: 129X1/SvJ * A/J * C57BL/6 * CBA) or (involves: 129X1/SvJ * BALB/c * C57BL/6 * CBA)
|
postnatal lethality, incomplete penetrance |
J:148174
|
Vhltm1Lss/Vhltm1Lss
Tg(Pdx1-cre)89.1Dam/0
involves: 129X1/SvJ * C57BL/6 * CBA
|
abnormal exocrine pancreas morphology |
J:148174
|
|
abnormal pancreatic islet morphology |
J:148174
|
|
increased pancreas adenoma incidence |
J:148174
|
|
pancreas cyst |
J:148174
|
|
postnatal lethality, incomplete penetrance |
J:148174
|
Vhltm1Mcs/Vhltm1Mcs
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
abnormal common myeloid progenitor cell morphology |
J:130780
|
|
abnormal erythropoiesis |
J:130780
|
|
abnormal liver morphology |
J:130780
|
|
abnormal spleen morphology |
J:130780
|
|
decreased spleen white pulp amount |
J:130780
|
|
normal
hematopoietic system phenotype |
J:130780
|
|
increased angiogenesis |
J:130780
|
|
increased erythrocyte cell number |
J:130780
|
|
increased erythroid progenitor cell number |
J:130780
|
|
increased hematocrit |
J:130780
|
|
increased hemoglobin content |
J:130780
|
|
increased leukocyte cell number |
J:130780
|
|
increased megakaryocyte cell number |
J:130780
|
|
increased spleen red pulp amount |
J:130780
|
|
increased spleen weight |
J:130780
|
|
normal
neoplasm |
J:130780
|
|
polycythemia |
J:130780
|
|
prenatal lethality, incomplete penetrance |
J:130780
|
|
pulmonary hypertension |
J:130780
|
Vhltm1Wml/Vhl+
involves: 129S4/SvJae * C57BL/6
|
increased incidence of tumors by chemical induction |
J:88492
|
Vhltm1Wml/Vhltm1Wml
involves: 129S4/SvJae * C57BL/6
|
abnormal placenta development |
J:42486
|
|
abnormal placental labyrinth vasculature morphology |
J:42486
|
|
abnormal trophoblast layer morphology |
J:42486
|
|
embryonic lethality during organogenesis, complete penetrance |
J:42486
|
|
placenta hemorrhage |
J:42486
|
Excel File
Analysis Tools